Существуют более эффективные и более безопасные методы предотвращения рака шейки матки.
Прививка особо опасна для спортсменов.
Источники
1.
Rintala MA et al. Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol. 2005;43(1):376-81
2.
Meites E et al. Use of a 2-dose schedule for human papillomavirus vaccination – updated recommendations of the advisory committee on immunization practices. MMWR. 2016;65(49):1405-8
3.
Margaret Stanley PD. Preventing cervical cancer: how much HPV vaccine do we need? Vaccine. 2018;36(32):4759-836
4.
Colafrancesco S et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013;70(4):309-16
5.
Fredericks DN et al. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev. 1996;9(1):18–33
6.
Daling JR et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002;84(2):263-70
7.
Haverkos H et al. The cause of invasive cervical cancer could be multifactorial. Biomed Pharmacother. 2000;54(1):54-9
8.
Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186-92
9.
Tomljenovic L et al. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des. 2013;19(8):1466-87
10.
Hildesheim A et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol. 1999;180(3 Pt 1):571-7
11.
Mahmud SM et al. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol. 2014;32(5):438-43
12.
Tomljenovic L et al. Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil. J Law Med Ethics. 2012;40(3):673-81
13.
Tomljenovic L et al. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med. 2013;45(2):182-93
14.
Inbar R et al. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil. Immunol Res. 2017;65(1):136-49
15.
Geier DA et al. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol. 2015;34(7):1225-31
16.
Rodríguez-Galán MA et al. Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011). An Pediatr (Barc). 2014;81(5):303-9
17.
Geier DA et al. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database. Immunol Res. 2017;65(1):46-54
18.
Liu XC et al. Adverse events following HPV vaccination, Alberta 2006-2014. Vaccine. 2016;34(15):1800-5
19.
Markowitz LE et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016;137(3):e20151968
20.
Fischer S et al. Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination. Oncol Lett. 2016;12(1):601-10
21.
Giambi C et al. A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. BMC Infect Dis. 2013;13:74
22.
Mollers M et al. Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands. Am J Epidemiol. 2014;179(10):1236-46
23.
Guo F et al. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccin Immunother. 2015;11(10):2337-44
24.
Peter C Gøtzsche. Complaint to the European Medicines Agency (EMA) over maladministration at the EMA. Nordic Cochrane Centre
25.
Brinth LS et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015; 33(22):2602-5
26.
Brinth L et al. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J. 2015;62(4):A5064
27.
Palmieri B et al. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017;65(1):106-16
28.
Kinoshita T et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014; 53(19):2185-200
29.
Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol. 2014;21(1):135-9
30.
Shaw LTC. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental? Pharma Reg Affairs. 2012:S12-001
31.
Little DT et al. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Rep. 2014;2(4):2324709614556129
32.
DeLong G. A lowered probability of pregnancy in females in the USA aged 25-29 who received a human papillomavirus vaccine injection. J Toxicol Environ Health A. 2018; 81(14):661-74
33.
McInerney KA et al. the effect of vaccination against human papillomavirus on fecundability. Paediatr Perinat Epidemiol. 2017;31(6):531-6
34.
Gajdová M et al. Delayed effects of neonatal exposure to Tween 80 on female reproductive organs in rats. Food Chem Toxicol. 1993;31(3):183-90
35.
Azmin MN et al. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol. 1985;14(3):238-42
36.
Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14
37.
Alade SL et al. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-7
38.
www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf
